Understanding the Market | EVEREST MED-B rose over 3% and announced the launch of the production construction project for Iqymod at its factory in Jiashan
I'm PortAI, I can summarize articles.
EVEREST MED-B's stock price rose by more than 3%, with an increase of 2.86% as of the time of writing, reported at HKD 59.4, with a transaction volume of HKD 129 million. The company announced the launch of the production construction project for Iqmodem at the Jiaxing factory, with a total investment of 70 million yuan, and an expected annual production capacity of 50 million pieces, supplying regions including mainland China, Hong Kong, Macau, Taiwan, South Korea, and Singapore. This medication is used for the treatment of moderate to severe active ulcerative colitis, characterized by good safety and rapid onset of action
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments